Delivery Order SPE2DB22D1106-SPE2DB25FERV5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,249.80 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,419.46 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) on August 20, 2025, with completion expected by August 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement action under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $7,847.44 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on June 4, 2025, with completion expected by June 5, 2025. This non-competitive delivery order is priced on a firm fixed-price basis and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $2,053.56 delivery order to AmerisourceBergen Drug Corp for Xifaxan 550 mg tablets (60-count) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xifaxan 550 mg tablets (60-count units) on June 26, 2025, with a ceiling value of $20,364.81 and a firm fixed price structure. This non-set-aside contract represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999 and extends through December 2026. The place of performance is located...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,985.98 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units). This non-set-aside, competitively awarded contract utilizes firm fixed price terms with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery from its Pennsylvania facility. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $24,690.56 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor for delivery to the Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,352.39 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xifaxan 550 mg tablets (60-count packaging). This non-set-aside, firm fixed-price delivery order is scheduled for completion by July 21, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, fulfills...
- The Defense Logistics Agency awarded a competitive delivery order valued at $4,651.90 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This order will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania, using firm fixed pricing with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed-price contract valued at $8,401.76, with an ultimate completion date of August 20, 2025. This non-set-aside competitive award was issued on August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FERV5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,344.55 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on June 4, 2025, with a completion date of June 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.9 million through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's portfolio under the DLA prime contract encompasses a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Xifaxan, an antibiotic used to treat traveler's diarrhea and hepatic encephalopathy, exemplifies AmerisourceBergen's role in fulfilling specialized pharmaceutical requirements for Defense Health Agency and other government healthcare systems through flexible contract vehicles designed to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.3k | 6/4/25 |